At a glance
- The two factors that actually decide EDC fit are the ones listicles bury: how fast a non-programmer can build and amend a study, and how much of the Part 11 validation burden the vendor already carries.
- A feature-count checklist is the wrong way to choose. Most EDC platforms tick the same boxes; the difference is build speed and who owns validation.
- “Part 11 compliant” is not a switch you buy. The system must support Part 11 controls; you still validate and operate it.
- Free and open-source EDC is real, but the catch is that the validation and hosting burden shifts to you, which is often the largest hidden cost.
- The right pick depends on team profile. A lean biotech and a global multi-site sponsor should not buy the same platform.
Every “best EDC software” page is a roundup of logos with one-paragraph blurbs that treat “Part 11 compliant” as a checkbox, gloss over how long it takes to build and amend a study, and file “free EDC” as a feature rather than a risk transfer. This guide evaluates EDC the way buyers actually feel the cost in month three: by study-build and amendment speed and by who carries the validation burden. It names real platforms, attributes claims honestly, and gives you a selection framework and checklist. It does not re-explain what EDC is conceptually (see the EDC concept guide) or compare CTMS project-management features.
What EDC software actually is (and what it is not)
EDC software captures clinical trial data into electronic case report forms and manages the edit-check, query, and lock workflow. Because an eCRF is an electronic record, EDC sits squarely under 21 CFR Part 11, which sets the criteria for treating electronic records and signatures as trustworthy and reliable equivalents to paper (21 CFR 11.1(a)). That regulatory footing is exactly why EDC is a distinct category from the systems it is often confused with.
EDC vs CTMS vs eTMF vs CDMS, where the data lives
- EDC holds the study data (the eCRFs).
- CTMS manages operations: sites, visits, timelines, tasks.
- eTMF stores essential documents and records.
- CDMS is the broader data-management environment EDC often lives within.
Buying EDC to do CTMS work, or vice versa, is the most common and most expensive category error. Keep the data layer (EDC) separate from the operational layer (CTMS) in your evaluation.
The seven criteria that actually separate EDC platforms
Study-build and amendment speed (configuration vs programming)
This is the cost driver buyers underestimate. The question is whether a data manager can build and amend a study by configuration, or whether every change needs a programmer and a release cycle. Mid-study amendments are inevitable, and a platform where an amendment takes weeks of programming will dominate your total cost. Ask every vendor to demonstrate a live amendment, not a slide about one.
Validation and 21 CFR Part 11, what the vendor carries vs what you still own
This is the criterion the listicles flatten into a checkbox. Part 11 requires, for closed systems, validation of systems to ensure accuracy, reliability, and the ability to discern invalid or altered records, plus audit trails, access control, copies for inspection, and record protection through retention (21 CFR 11.10). The key insight: those are obligations you operate, not features you buy. A vendor can validate its base platform, but your study-specific configuration, your edit checks, your user access, still has to be validated and operated by you. FDA’s eSource guidance frames the operating responsibility plainly: adequate controls should be in place to ensure the reliability, quality, and integrity of the electronic source data, and sponsors should describe the intended use of computerized systems, the security measures, and the data flow in the protocol or data management plan (FDA eSource, §IV). So the real question is not “are you Part 11 compliant?” but “what part of validation do you carry, and what is left to me?”
ePRO, eConsent, and eSource integration
Modern trials capture data from patients and devices, not just site staff. FDA’s eSource guidance explicitly contemplates patient-reported outcome instruments transmitting data directly to the eCRF (with the subject as the data originator) and electronic health record data flowing into the eCRF (FDA eSource, §III.A.2). Whether your EDC handles ePRO, eConsent, and eSource natively or needs bolt-ons affects both cost and data integrity, because every integration is another place the audit trail and data element identifiers must hold (FDA eSource, §III.A.3).
Interoperability (CTMS, eTMF, lab, APIs)
EDC does not live alone. Evaluate how cleanly it exchanges data with your CTMS, eTMF, and central labs, and whether it offers real APIs. Poor interoperability means manual re-entry, which reintroduces exactly the transcription errors EDC exists to remove.
Pay particular attention to data portability at study end. You will need to extract a complete, accurate dataset for analysis, archiving, and inspection, and Part 11 expects the system to generate accurate and complete copies of records in both human-readable and electronic form suitable for inspection (21 CFR 11.10). A platform that makes export painful, or that locks your data in a proprietary format, becomes a problem precisely when you can least afford one: at database lock and archiving. Ask, in the demo, to see a full study export and confirm what formats it supports.
Usability for sites and data managers; pricing model
Site usability drives data quality: a confusing eCRF produces more queries. And pricing models vary widely (per-study, per-form, per-user, per-month), so model your real study shape before comparing headline numbers.
Best EDC software, by team profile
Rather than rank, match the platform to the team. Treat every capability and pricing claim below as the vendor’s own marketing, to be verified in a demo against the criteria above.
Lean / small-biotech and academic picks
Platforms positioned for fast configuration and lower entry cost include Viedoc, Castor, and Medrio, with Captivate (formerly ClinCapture) and OpenClinica also positioned for smaller or budget-conscious teams. The differentiator for lean teams is build speed and how much validation the vendor absorbs.
Enterprise / global multi-site picks
For large, multi-site, multi-study programs, the commonly cited platforms are Medidata Rave, Oracle Clinical One, and Veeva Vault EDC. These emphasize scale, integration breadth, and established validation packages, typically at higher cost and complexity.
Specialty considerations (oncology, rare disease, device)
Oncology (complex dosing, adjudication), rare disease (small N, decentralized), and device studies have specific needs; weight the criteria accordingly (for example, amendment speed matters more in adaptive oncology designs).
Free and open-source EDC: when it fits, and the hidden cost
Free and open-source EDC (OpenClinica has a community edition, for example) is genuinely usable, but the catch is structural, not cosmetic. Part 11 requires the system to be validated and operated with full controls regardless of license (21 CFR 11.10(a)), so choosing “free” does not remove the validation work; it transfers it, along with hosting, security, and maintenance, onto you. For a team with the technical capacity to validate and host, that can be a fair trade. For a team without it, “free” is often the most expensive option once the validation effort is counted.
How EDC is priced (and the cost behind the sticker)
EDC pricing rarely reduces to one number, which is why headline comparisons mislead. Common models include per-study, per-form or per-eCRF, per-site, per-month, and tiered subscriptions, sometimes combined. The variables that move the real cost are the number of studies and sites, study duration (longer trials accrue more subscription months), and how amendments are charged, because a vendor that bills professional-services hours for every mid-study change can quietly dwarf the license fee. Before comparing two quotes, model your actual study shape, sites, forms, expected amendments, and duration, then ask each vendor to price that scenario, not a generic one. The cheapest sticker with expensive amendments is often the costliest platform over a multi-year trial.
Adoption: build, validate, train, go live
Choosing the platform is half the work; standing it up is the other half. Adoption runs in four moves: build the study (eCRFs, edit checks, roles), validate the study-specific configuration, train sites and data managers, and go live. The validation step is the one teams underestimate, and it is non-negotiable: Part 11 requires validation to ensure accuracy, reliability, and the ability to discern invalid or altered records regardless of platform (21 CFR 11.10(a)), and your study-specific configuration is yours to validate even if the vendor validated the base product. Plan for it, and favor a platform where a data manager can build and amend by configuration, because every amendment re-triggers a slice of that validation work. Site usability matters here too: a clean, well-built eCRF reduces queries from day one, while a confusing one generates a backlog you will be cleaning until database lock.
A short EDC selection checklist
- Can a data manager build and amend a study without a programmer? (demo it)
- What validation does the vendor carry, and what must we validate? (get it in writing)
- Does it support our ePRO/eConsent/eSource needs natively?
- Does it integrate with our CTMS, eTMF, and labs via real APIs?
- Is the eCRF genuinely usable for sites? (test with a site user)
- Does the pricing model fit our study shape, not just the headline number?
- For free/open-source: do we have the capacity to validate and host it ourselves?A note on boundaries: TrialTrack is clinical project-management software, not an EDC. It does not capture study data; it sits alongside your EDC to manage sites, visits, and tasks. Do not evaluate it as an EDC option.
The bottom line
Choose EDC by the two things you will feel in month three: how fast a non-programmer can build and amend the study, and how much of the Part 11 validation burden the vendor carries versus what you still own. Match the platform to your team profile rather than a top-ten list, treat “free” as a transfer of validation work rather than a saving, and remember that “Part 11 compliant” describes a capability, not your compliance. Validate and operate the system well, and the EDC earns its place; buy on feature count alone, and you will pay for it at the first amendment.
Sources
Dejan Murko
Dejan is the co-founder of Mayet, building software for biotech and pharma teams.